0001372514 false 0001372514 2021-12-14 2021-12-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares












Date of report (Date of earliest event reported): December 14, 2021



(Exact name of registrant as specified in its charter)



(State or other jurisdiction of incorporation)


001-36672   98-0443284
(Commission File Number)   (IRS Employer Identification No.)



1371 East 2100 South

Suite 200

Salt Lake City, Utah 84105 



(Address of principal executive offices)   (Zip Code)


(781) 788-9043

(Registrant’s telephone number, including area code)


(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class:   Trading Symbol(s)   Name of each exchange on which registered:
Common Stock, $0.01 par value   KPRX   The Nasdaq Capital Market


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨







Item 8.01. Other Events.


On December 14, 2021, Kiora Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that the Company has received topline data from its vehicle-controlled, randomized safety study of KIO-101 eyedrops in 24 healthy subjects and 21 patients diagnosed with ocular surface inflammation.


The press release is filed as Exhibit 99.1 and investors should read the press release in its entirety, including the cautionary statements regarding forward looking statements therein.


Item 9.01.
Financial Statements and Exhibits.


(d) Exhibits.


The Company hereby files or furnishes, as applicable, the following exhibits:


99.1 Press Release of the Company, dated as of December 14, 2021
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)







Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


  By: /s/ Brian M. Strem, Ph.D.
    Brian M. Strem, Ph.D.
    President and Chief Executive Officer
  Date: December 14, 2021




EX-99.1 2 tm2135356d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1



Kiora Reports KIO-101 is Safe and Tolerable; Topline Data Supports Advancing KIO-101 to a Phase 2 Study in Patients with Dry Eye Disease


SALT LAKE CITY, UT, Dec 14, 2021 – Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (“Kiora” or the “Company”) announced topline data from its vehicle-controlled, randomized safety study of KIO-101 eyedrops. The study evaluated 24 healthy subjects and 21 patients diagnosed with ocular surface inflammation, a key driver of dry eye disease. The results demonstrated favorable safety and tolerability of KIO-101 as well as statistically significant improvements in conjunctival hyperemia, a key inclusion criterion for the 21 patients enrolled with ocular surface inflammation and a recognized clinical sign in patients with ocular surface inflammation and associated dry eye. These results warrant advancing KIO-101 into Phase 2 studies of longer duration. KIO-101 is a small molecule DHODH inhibitor representing a novel approach to addressing ocular inflammation and dry eye disease. Previous generations of DHODH inhibitors are currently approved to treat patients with the systemic autoimmune diseases, multiple sclerosis and rheumatoid arthritis.


“As an exploratory study, our predetermined analysis plan was limited to only formal comparisons between groups for pharmacokinetics, safety and tolerability. A post-hoc analysis on predefined secondary efficacy outcomes showed a meaningful reduction in conjunctival hyperemia, consistent with inhibition of both T-cell proliferation and proinflammatory cytokine release that we would expect from an immune modulating DHODH inhibitor,” said Eric J Daniels, MD, Chief Development Officer of Kiora. “These early signs of a drug-related effect on clinical outcomes are encouraging and support KIO-101’s continued development for patients with ocular surface inflammation associated with dry eye disease.”


The topline results and observations include the following:


·KIO-101 had a favorable safety and tolerability profile with no systemic serious adverse events (SAE) or ocular SAEs in any subjects tested.
·Pharmacokinetic analysis demonstrated no detectable levels of KIO-101 in the plasma in the majority of subjects, consistent with the design of Kiora’s ophthalmic formulation.
·Treatment with KIO-101 resulted in a statistically significant and clinically meaningful reduction in conjunctival hyperemia, an FDA accepted pivotal study “sign endpoint” for dry eye disease.
oResults showed at day 13, 100% of patients treated with KIO-101 (14/14) saw a reduction >1 from baseline, measured on the Efron scale (0-5), versus only 42.8% with vehicle control (3/7) (p < 0.006).
oThe mean reduction in conjunctival hyperemia score from baseline to day 13 demonstrated statistical significance in active vs. vehicle control (-1.055 vs. -0.604; p = 0.0316).
oThis apparent drug effect on conjunctival hyperemia was lost when patients were assessed at the Day 20 post-treatment follow-up, 8 days after the last dose was administered.
·There was a numerical trend favoring KIO-101 in ocular surface disease index (OSDI), but no statistically significant differences were observed in tear break up time (TBUT), corneal staining, conjunctival staining nor other exploratory endpoints. A larger sample size and dosing period longer than two weeks is necessary to effectively evaluate a statistical drug effect on these efficacy endpoints.
·Additional data will be submitted for presentation at an upcoming scientific/medical conference.







Trial Design


The randomized, double-masked, vehicle-controlled, single site study was conducted in Vienna, Austria and led by Principal Investigator Gerhard Garhöfer, MD, Associate Professor, Medical University of Vienna. The trial was designed to evaluate the safety and tolerability of KIO-101 in patients with ocular surface inflammation. A total of 21 patients were treated BID for 12 days with 0.15% of KIO-101 (n=14) or vehicle (n=7). The key inclusion criteria were conjunctival hyperemia score >2 and an OSDI of > 22. Primary endpoints included safety and tolerability. Secondary and exploratory endpoints included pharmacokinetics of KIO-101 as well as OSDI, conjunctival hyperemia, TBUT, corneal staining (Fluorescein), and conjunctival staining (Lissamine Green), ocular discomfort, lid edema, lid erythema.


This followed the Phase 1 dose-ascending portion of the study in healthy volunteers, in which a total of 24 subjects were randomized to receive KIO-101 (0.05%, 0.15%, and 0.30%) or vehicle. Key endpoints assessed were safety, tolerability and plasma pharmacokinetics of KIO-101 following 1 day (single dose) and 12 days (48 doses).


About Kiora


Kiora is a clinical-stage biotechnology company developing and commercializing products for treating ophthalmic diseases. KIO-301 is a molecular photoswitch that has the potential to restore light perception in patients with inherited and/or age-related retinal degeneration. KIO-101 is a next-generation, non-steroidal, immuno-modulatory and small molecule inhibitor of Dihydroorotate Dehydrogenase (“DHODH”) with best-in-class picomolar potency and a validated immune modulating mechanism (blocks T cell proliferation and proinflammatory cytokine release) designed to overcome the off-target side effects and safety issues associated with other DHODH inhibitors. In addition, Kiora is developing KIO-201, a modified form of the natural polymer hyaluronic acid, designed to accelerate corneal wound healing. For more information, please visit www.kiorapharma.com.


Forward-Looking Statements


Some of the statements in this press release are “forward-looking” and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These “forward-looking” statements include statements relating to, among other things, the development and commercialization efforts and other regulatory or marketing approval efforts pertaining to Kiora’s products, including KIO-101, KIO-201 and KIO-301, as well as the success thereof, with such approvals or success may not be obtained or achieved on a timely basis or at all. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, market and other conditions and certain risk factors described under the heading “Risk Factors” contained in Kiora’s Annual Report on Form 10-K filed with the SEC on March 25, 2021 or described in Kiora’s other public filings. Kiora’s results may also be affected by factors of which Kiora is not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. Kiora expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions, or circumstances on which any such statement is based, except as required by law.







Investor Contact


Francina Agosti, PhD

(617) 546-0742





EX-101.SCH 3 kprx-20211214.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 kprx-20211214_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 kprx-20211214_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2135356d1_ex99-1img01.jpg GRAPHIC begin 644 tm2135356d1_ex99-1img01.jpg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end XML 7 tm2135356d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001372514 2021-12-14 2021-12-14 iso4217:USD shares iso4217:USD shares 0001372514 false 8-K 2021-12-14 KIORA PHARMACEUTICALS, INC. DE 001-36672 98-0443284 1371 East 2100 South Suite 200 Salt Lake City UT 84105 84105 781 788-9043 false false false false Common Stock, $0.01 par value KPRX NASDAQ false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Dec. 14, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 14, 2021
Entity File Number 001-36672
Entity Central Index Key 0001372514
Entity Tax Identification Number 98-0443284
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1371 East 2100 South
Entity Address, Address Line Two Suite 200
Entity Address, City or Town Salt Lake City
Entity Address, State or Province UT
Entity Address, Postal Zip Code 84105
City Area Code 781
Local Phone Number 788-9043
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.01 par value
Trading Symbol KPRX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( $XXCE,'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !..(Y35\?>$NX K @ $0 &1O8U!R;W!S+V-O&ULS9+! M3L,P#(9?!>7>NLF 0]3E N*T24A, G&+$F^+:)HH,6KW]K1AZX3@ 3C&_O/Y ML^361&E"PN<4(B9RF&]&W_59FKAF1Z(H ;(YHM>YGA+]U-R'Y#5-SW2 J,V' M/B"(IKD'CZ2M)@TSL(H+D:G6&FD2:@KIC+=FPNPI Z\Y,#5/ MC*>Q:^$*F&&$R>?O MJ%6*I_8DL'V#DY9K>DAF&HAU7)33MP>-MN7LJZE>LS MZ=[@]"L[2:>(:W:9_+IZ>-P],24:P2LN*GZ[XT(V0HJ[]]GUA]]5V ?K]NX? M&U\$50N_[D)] 5!+ P04 " !..(Y3F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M $XXCE,1N.,\300 -00 8 >&PO=V]R:W-H965T&UL MG9A=<^(V%(:OM[]"P_2BG4EBRSB![!!F',+N,OFBF'0[[?1"V (TL2U7DD/R M[WMDB$VSYICI39!LG]>/SI%?21ELI'K6:\X->4V33%]UUL;DGQU'1VN>,GTF M=4)Z.=K M[]P&E$_\+OA&[[6)'5?LMD^ MZ_L=$A7:R'07# 2IR+:_['67B+V KGL@P-L%>"7W]D4EY0TS;#A0PT$9!H?Y&)+N59+>4] \ARJB Z6/(_"WG32/$ MP_NGMPB$7T'XJ$H !'%)\25AJR8*/'[)$LT1CO.*X_RX9$RY$C(FXRPF,%\: M\]*BM*O\3Y\^M=3^HF*[0!7'F1'FC7P1"2'H5 M3^\8GAE?"3L;(6D/+&W,%*YS.WF-2M_HGXSQB#W3)D> QG$L>):G[PWR!T\1QZS9C)<$DI,R9AI0SSJNB2$%7J- ML=;.3;W_SSK?R$967#(L!%0#-A888+T.4-S)/P*.; ]*/9>;K!$.EPM98L@= M>^:E$$98+Q(4=_F/A-5LG"KY(K*HN=ZXYM,<0ZO7#8K;_4>TJ=0&[.9/D1_^ M1'#%OD_=) <4__KH0Q/(/$I&F1[2Q8-U+A0FT;$%HO#!3W\5 F(A)& M9"MR#]-;"98T\N J;3Q>O1!XN%5/%3^-(#T!/\AC'5]NX=9>_CE*N5S=)74#!K M:QLYRYH+B@L>G&3.WAG5GO?OF7VC)@E?@I![U@-=M3U";SM&YN6Q=2$-'(++ MYIHS^ #L W!_*:5Y[]B3&PO9KEMWDOSAR+DCO9*Z MW="C<\W[)&D/1ZY8^\XT7'ND,E8QYU5;)VUC.2M;<%(R6=[<9(EB0M-BK3MU MIUQ+#J;3;D-O:%*L*Z//EI0&@U_*%">/3&[HEDFQMV)8RY20IV!>@N%@I+'$ M>2I\0Q=@:9\"O @:L!SC**&-!6,2,H3O_;C\&3!IK5>%E#/!)0V&8MTPY[C5 M=UX9%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.'36-/+T M08I:*Q[V_LL)BS6;_,C16/'DL\&D'+R!6TH>N77B<&GY85FSX[V;IJFO<,[+ M?Y#SGZUSS36W3%Z2]J/_-U?Y+8R3\?1<'-&K SI;"5R$&_H5[E=YYD#VG9!. MZ%$[BK+D^L4Y]>$=V_L+_"J^7U_RBG72[69P0\_R%UZ*3N7SJGNHR[CJ+'^& M^VB1S;>PSR5TR7M>;D?5UOM!)%[P6<<'')XC=\,31S"?@,41P+ \& /,)WAA M>?ZG_:S0_00,X[:*(BO49X7Z!*\8LAT^6)ZX3^Z?^$[S/$VS#*OH=AMEL,7J MEF7P%X^&<0,/+ ]D>ENM\6[C$_+Z'& ]?6U"L)WBDXCM%*\U(/&Z@4>>Q[N- MY0$/K O8[$#^>!Z8J;A/FD)7,6[8"<:1/,<0F,7XC&894IT,/O'^8* \^>Q\ETWLJ.?]74_P$4$L#!!0 ( $XX MCE.7BKL

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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://eyegatepharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2135356d1_8k.htm kprx-20211214.xsd kprx-20211214_lab.xml kprx-20211214_pre.xml tm2135356d1_ex99-1.htm http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2135356d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tm2135356d1_8k.htm" ] }, "labelLink": { "local": [ "kprx-20211214_lab.xml" ] }, "presentationLink": { "local": [ "kprx-20211214_pre.xml" ] }, "schema": { "local": [ "kprx-20211214.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "KPRX", "nsuri": "http://eyegatepharma.com/20211214", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2135356d1_8k.htm", "contextRef": "From2021-12-14to2021-12-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://eyegatepharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "tm2135356d1_8k.htm", "contextRef": "From2021-12-14to2021-12-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://eyegatepharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 15 0001104659-21-149386-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-21-149386-xbrl.zip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